1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy, Inc.

PFND
Pathfinder Cell Therapy, Inc.US flagOther OTC
0.00
USD
- -
- -
66,716.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.09
-0.06
-0.03
-0.03
-0.05
-0.05
-0.05
-0.04
- -
-0.02
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.06
-0.04
-0.03
-0.03
-0.04
-0.04
-0.04
-0.03
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.4
-1.17
-0.75
-0.68
-0.61
-0.62
-0.63
-0.61
- -
-0.02
-0.02
-0.02
-0.03
-0.03
Tangible Book Value per Share
-0.04
-0.01
0.02
- -
0.04
0.03
0.03
0.01
- -
- -
- -
-0.01
-0.01
-0.01
Basic Weighted Avg Shares
16
34
56
65
79
85
90
101
458
526
667
667
667
667
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-10,339.13
- -
-3,193.66
-3,988.81
-2,527.07
-1,144.44
- -
-4,956.16
-1,807.02
-2,961.11
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-2
-2
-4
-5
-4
-4
-1
-11
-2
-2
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-8,004.35
- -
-2,742.96
-3,450
-2,433.15
-1,139.72
- -
-15,438.36
-1,891.23
-3,157.41
- -
- -
Working Capital
- -
- -
1
- -
3
3
3
1
-1
-1
-3
-5
-6
-7
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-1
- -
1
- -
3
3
3
1
-1
-1
-3
-5
-6
-7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
667
667
667
Market Capitalization
2
3
5

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
7
Payables & Accruals
1
1
1
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
233.14%
24.54%
30.59%
Free Cash Flow
11.81%
5.94%
-39.85%
Net Income, GAAP
68.76%
116.49%
-18.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Richard L. Franklin
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
12 Bow Street Cambridge MA United States of America 02138
IPO Date
Jan 3, 2000
CIK
0000889428
Website
pathfindercelltherapy.com
Similar Companies
Aravive, Inc. (ARAV)
Onconic Therapeutics (476060.KQ)
Apollomics, Inc. (APLM)
Kalaris Therapeutics Inc (KLRS)
Meribank Biotech Co., Ltd (4724.TWO)
Nexera Technologies Ltd (NEXR)
Business
Pathfinder Cell Therapy, Inc. (PFND) is a development-stage regenerative medicine biotechnology company that develops novel cell-derived therapies for diseases characterized by organ-specific cell damage, including diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other related conditions; its proprietary platform targets pancreatic cells for diabetes, kidney cells for renal disease, cardiac stem cells for myocardial infarction, and vascular cells for peripheral vascular disease using advanced cell culture, tissue engineering, and regenerative medicine technologies. The company, founded in 2008 and headquartered at 12 Bow Street in Cambridge, Massachusetts, operates in the United States with a focus on preclinical research toward clinical trials and FDA approval, serving unmet needs in metabolic, renal, and cardiovascular segments through potential partnerships with pharmaceutical firms and research institutions. Pathfinder Cell Therapy maintains a minimal operational structure with one employee and leadership including CEO Dr. Richard L. Franklin, Chairman Joerg Gruber, and CFO John M. Benson; no major recent partnerships, funding rounds, acquisitions, product launches, or strategic expansions have been reported in the last one to two years, reflecting its ongoing development-stage status on the OTC market.